Natural course and therapy of acute hepatitis C virus infection: Can the progression to chronicity be prevented?;Verlauf und therapie der akuten hepatitis-C-virusinfektion. Ist eine pravention der chronifizierung moglich?

Zeitschrift fur Gastroenterologie

Volumn 38, Issue 5, 2000, Pages 387-395

  Jaeckel, E ^a   Manns, M P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute hepatitis; Daily dosing; Hepatitis C virus; Induction dosing; Interferon alfa 2; Lymphocytic chorionmeningitis virus; Needle stick injury; T cell tolerance; Transfusion

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN;

BLOOD TRANSFUSION; DISEASE COURSE; HEPATITIS C; HEPATITIS C VIRUS; INTRAVENOUS DRUG ABUSE; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NEEDLESTICK INJURY; REVIEW; VIRUS INFECTION; VIRUS TRANSMISSION;

ACUTE DISEASE; ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; TIME FACTORS;

EID: 0034083781     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-14882     Document Type: Review

References (47)

1. Poynard T, Bedossa P, Opolon P. Nutural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32
2. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998; 352: 1426-32
3. Reichard O, Norkrans G. Fryden A et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351: 83-7
4. Flegel WA, Koerner K, Wagner FF, Kubanek B. Zur HIV-Testung in Blutspendediensten. Dtsch Ärztebl 1996; 93: A816-21
5. Donahue JG, Muñoz A, Ness PM et al. The declining risk of posttransfusion hepatitis C virus infection. N Engl J Med 1992; 327: 369
6. Camma C, Almasio P, Craxi A. Interferon as treatment for acute hepatitis C. A meta-analysis. Dig Dis Sci 1996; 41: 1248-55
7. Alter MJ, Margolis HS, Krawczynski K et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899-1905
8. Mattsson L, Sonnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: A 13-year follow-up study of hepatitis C virus markers. Liver 1993; 13: 274-8
9. Sherlock S. Predicting progression of acute type-B hepatitis to chronicity. Lancet 1976; 2: 354-6
10. Sachithanandan S, Fielding JF. Jaundice at onset signifies a good prognosis in anti-D-associated HCV infection. Eur J Gastroenterol Hepatol 1997; 9: 77-9
11. Gerlach JT, Diepolder HM, Gruener NH et al. Natural course of sympomatic acute hepatitis C. J Hepatol 1999; 30 (suppl. 1): 120
12. Barrera JM, Bruguera M, Ercilla MG et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995; 21: 639-44
13. Rehermann B, Takaki A. Liebetrau A et al. Characterisation of the cytotoxic and helper T cell response in patients 18 years after a single source outbreak of HCV infection. Hepatology 1997; 26 (suppl. 2): 406A
14. Mazola M, Punzi G, Guastediseni A et al. Evolution of acute hepatitis C virus infection: A prospective study. J Hepatol 1999; 30 (suppl. 1): 136
15. Parana R, Cotrim H, Andrade Z et al. Natural history of acute sporadic hepatitis C in Brazil: 4-years follow-up study. Hepatology 1997; 26 (suppl.): 434A
16. Tremolada F, Casarin C, Alberti A et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992; 16: 273-81
17. Gordon SC, Elloway RS, Long JC, Dmuchowski CF. The pathology of hepatitis C as a function of mode of transmission: Blood transfusion vs. intravenous drug use. Hepatology 1993; 18: 1338-43
18. Wiese M. Natural course of hepatitis C study in an unselected group with identical infection. J Hepatol 1996; 25 (suppl. 1): 57
19. Power JP, Lawlor E, Davidson F et al. Hepatitis C viraemia in recipients of Irish intravenous anti-D immunoglobulin. Lancet 1994; 344: 1166-7
20. Mitsui T, Iwano K, Masuko K et al. Hepatitis C virus infection in medical personnel after needle stick accident. Hepatology 1992; 16: 1109-14
21. Arai Y, Noda K, Enomoto N et al. A prospective study of hepatitis C virus infection after needle stick accidents. Liver 1996; 16: 331-4
22. Kiyosawa K, Sodeyama T, Tanaka E et al. Hepatitis C in hospital employees with needle stick injuries. Ann Intern Med 1991; 115: 367-9
23. Zinkernagel RM. Immunology taught by viruses. Science 1996; 271: 173-8
24. Gallimore A, Glithero A, Godkin A et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med 1998; 187: 1383-93
25. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993; 362: 758-61
26. Oxenius A, Zinkernagel RM, Hengartner H. Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T-cells upon acute versus persistent viral infection. Immunity 1998; 9: 449-57
27. Katz MH, Gerberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N Engl J Med 1997; 336: 1097-100
28. Missale G, Bertoni R, Lamonaca V et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the antiviral cell-mediated immune response. J Clin Invest 1996; 98: 706-14
29. Diepolder HM, Gerlach JT, Zachoval R et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997; 71: 6011-9
30. Diepolder HM, Zachoval R, Hoffmann RM et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346: 1006-7
31. Gruener NH, Gerlach JT, Jung MC et al. HCV-specific gamma-interferon producing CD8+ T-cells contribute to viral clearance in acute hepatitis C. J Hepatol 1999; 30 (suppl. 1): 108
32. Rehermann B, Chang KM, McHutchison JG et al. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 1996; 98: 1432-40
33. Viladomiu L, Genesca J, Esteban JI et al. Interferon-alpha in acute posttransfusion hepatitis C: A randomized, controlled trial. Hepatology 1992; 15: 767-9
34. Lampertico P, Ruini M, Romeo R et al. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C. Hepatology 1994; 19: 19-22
35. Alberti A, Chemello L, Benvegnu L. Pilot study of Interferon alfa-2a in preventing chronic evolution of acute Hepatitis C. In: Viral Hepatitis and Liver Disease. Hollinger FB, Lemon S, Margolis H (eds.). Baltimore, Williams and Wilkins, 1992
36. Tassopoulos NC, Koutelou M, Papatheodoridis G et al. Treatment of acute non-A, non-B hepatitis with interferon alpha-2b. Infection 1992; 20: 242
37. Palmovic D, Kurelac I, Crnjakovic-Palmovic J. The treatment of acute post-transfusion hepatitis C with recombinant interferon-alpha. Infection 1994; 22: 222-3
38. Lee WM, Shiffman ML, Gnann JW, Samanta A, Alam J. A trial of interferon beta 1a for four weeks for therapy of acute hepatitis C. Hepatology 1996; 26 (suppl.)
39. Hwang SJ, Lee SD, Chan CY, Lu RH, Lo KJ. A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol 1994; 21: 831-6
40. Takano S, Satomura Y, Omata M. Effects of interferon beta on non-A, non-B acute hepatitis: A prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group. Gastroenterology 1994; 107: 805-11
41. Omata M, Yokosuka O, Takano S et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991; 338: 914-5
42. Ohnishi K, Nomura F, Nakano M. Interferon therapy for acute posttransfusion non-A, non-B hepatitis: Response with respect to anti-hepatitis C virus antibody status. Am J Gastroenterol 1991; 86: 1041-9
43. Lam N, Neumann AU, Gretch DR et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-31
44. Hadziyannis SJ, Tsantoulas D, Raptopolou M et al. Induction dosing with interferon 2 b: An International Study. Hepatology 1997; 26 (suppl. 1): A420
45. Vogel W, Graziadei I, Umlauft F et al. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: A pilot study. Dig Dis Sci 1996; 41 (12 suppl.): 81S-85S
46. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996; 24: 778-89
47. Hopf U, Niederau C, Kleber G, Fleig WE. The treatment of chronic viral hepatitis B/D and acute and chronic viral hepatitis C. The consensus of the German Society for Digestive and Metabolic Diseases. Z Gastroenterol 1997; 35: 971-86